VectivBio Holding AG Research and Development Expense
VectivBio Holding AG reported Research and Development Expense of $73.95 million for the 12-month period ending 2022-12-31, per its 20-F filed 2023-04-19.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2023-04-19
| Period end | Research And Development Expense 6 month | Research And Development Expense 12 month |
|---|---|---|
| 2022-12-31 | $73.95M 20-F · filed 2023-04-19 | |
| 2022-06-30 | $37.51M 6-K · filed 2022-10-13 | |
| 2021-12-31 | $50.18M 20-F · filed 2023-04-19 | |
| 2021-06-30 | $26.49M 6-K · filed 2022-10-13 | |
| 2020-12-31 | $43.03M 20-F · filed 2023-04-19 | |
| 2019-12-31 | $15.98M 20-F · filed 2022-04-07 |